Liom

Executive Summary

Liom is a Swiss MedTech company founded in 2021, pioneering non-invasive continuous glucose monitoring (CGM) technology. The company is developing a wearable device that integrates glucose data with broader health metrics such as fitness, cardiovascular health, sleep, and mental focus analytics. Its core mission is to enable preventative health management by making metabolic awareness seamless and accessible without skin-piercing sensors. Despite being in an early stage with no disclosed funding or valuation, Liom operates in a rapidly growing market for non-invasive CGM, which has attracted significant interest from investors and strategic partners. The company's differentiation lies in its multi-metric approach, combining glucose monitoring with other wellness indicators. However, given the lack of public milestones, clinical data, or product launch timelines, the venture carries high technological and regulatory risk.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Round55% success
• Q2 2027First Clinical Feasibility Study Results45% success
• H1 2027Partnership with Digital Health Platform40% success